PT - JOURNAL ARTICLE AU - Polosa, R. AU - Tomaselli, V. AU - Ferrara, P. AU - Romeo, A. C. AU - Rust, S. AU - Saitta, D. AU - Caraci, F. AU - Romano, C. AU - Thangaraju, M. AU - Zuccarello, P. AU - Rose, J. AU - Ferrante, M AU - Belsey, J. AU - Cibella, F. AU - Interlandi, E. AU - Ferri, R. TI - POPULATION-BASED SERO-EPIDEMIOLOGICAL STUDY PROTOCOL FOR THE IMPACT OF SMOKING ON SARS-COV-2 INFECTION AND COVID-19 OUTCOMES – THE TROINA STUDY AID - 10.1101/2021.04.29.21256236 DP - 2021 Jan 01 TA - medRxiv PG - 2021.04.29.21256236 4099 - http://medrxiv.org/content/early/2021/05/03/2021.04.29.21256236.short 4100 - http://medrxiv.org/content/early/2021/05/03/2021.04.29.21256236.full AB - After the global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), research has highlighted several aspects of the pandemic, focusing on clinical features and risk factors associated with infection and disease severity. However, emerging results on the role of smoking in SARS-CoV-2 infection susceptibility or COVID-19 outcomes are conflicting, and their robustness remains uncertain. In this context, this project aims at quantifying the proportion of SARS-CoV-S antibody seroprevalence, studying the changes in antibody levels over time, and analyzing the association between smoking status and infection using seroprevalence data.The added value of this research is that the current smoking status of the population to be studied will be biochemically verified, in order to avoid the bias associated with self-reported smoking status. As such, the results from this survey may provide actionable metric to study the role of smoking in SARS-CoV-2 spread, and therefore implement the most appropriate public health measures to control the pandemic.The research design involves a 6-month prospective cohort study with serial sampling of the same individuals. Each participant will be surveyed about their demographics and COVID-19-related information, and blood sampling will be collected upon recruitment and at specified follow-up time points (namely, after 8 and 24 weeks). Blood samples will be screened for the presence of SARS-CoV-2 specific antibodies and serum cotinine.Overall, we expect to find a higher prevalence of antibodies in individuals at high-risk for viral exposure (i.e., healthcare or other essential workers), according to previous literature, and to refine current estimates on the association between smoking status and SARS-CoV-2/COVID-19. Our results may serve as a reference for future clinical research and the methodology could be exploited in public health sectors and policies.Competing Interest StatementRP is full tenured professor of Internal Medicine at the University of Catania (Italy) and Medical Director of the Institute for Internal Medicine and Clinical Immunology at the same University. In relation to his recent work in the area of respiratory diseases, clinical immunology, and tobacco control, RP has received lecture fees and research funding from Pfizer, GlaxoSmithKline, CV Therapeutics, NeuroSearch A/S, Sandoz, MSD, Boehringer Ingelheim, Novartis, Duska Therapeutics, and Forest Laboratories. Lecture fees from a number of European EC industry and trade associations (including FIVAPE in France and FIESEL in Italy) were directly donated to vaper advocacy no−profit organizations. RP has also received grants from European Commission initiatives (U−BIOPRED and AIRPROM) and from the Integral Rheumatology & Immunology Specialists Network (IRIS) initiative. He has also served as a consultant for Pfizer, Global Health Alliance for treatment of tobacco dependence, CV Therapeutics, Boehringer Ingelheim, Novartis, Duska Therapeutics,ECITA (Electronic Cigarette Industry Trade Association, in the UK), Arbi Group Srl., and Health Diplomats. RP has served on the Medical and Scientific Advisory Board of Cordex Pharma, Inc., CV Therapeutics, Duska Therapeutics Inc, Pfizer, and PharmaCielo. RP is also founder of the Center for Tobacco prevention and treatment (CPCT) at the University of Catania and of the Center of Excellence for the acceleration of Harm Reduction (CoEHAR) at the same University, which has received support from Foundation for a Smoke Free World to conduct 8 independent investigator−initiated research projects on harm reduction. RP is also currently involved in the following pro bono activities, scientific advisor for LIAF, Lega Italiana Anti Fumo (Italian acronym for Italian Anti−Smoking League), the Consumer Advocates for Smoke−free Alternatives (CASAA) and the International Network of Nicotine Consumers Organizations (INNCO), Chair of the European Technical Committee for standardization on Requirements and test methods for emissions of electronic cigarettes (CEN/TC 437, WG4). JR: Research support from Foundation for a Smoke−Free World, Philip Morris International, Altria, JUUL Labs. Consulting with Revive pharmaceuticals, and consulting and patent purchase agreement with Philip Morris International. All other authors have no relevant conflict of interest to declare in relation to this study.Clinical TrialN.A.Funding StatementThis investigator−initiated research protocol was produced with the help of a grant from the Foundation for a Smoke Free World. The funder had no role in the study design, or the writing of the protocol. The contents, selection and presentation of facts, as well as any opinions expressed in the protocol are the sole responsibility of the author and under no circumstances shall be regarded as reflecting the positions of the funder.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Comitato Etico IRCCS Sicilia - Oasi Maria SS 2020/06/16/CE-IRCCS-OASI/31All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, RP, upon reasonable request.